

REMARKS

Claim 37 has been amended. These claims add no new matter and recite antigen TBH9-FL, SEQ ID NO:107 (*see, e.g.*, specification, page 40, lines 24-27).

In response to the Restriction Requirement, Applicants elect to prosecute Group I, claims 37-41 and 55. The foregoing election is made with traverse, as the three groups set forth by the Examiner all stem from a common concept and theory, and are thus related. As such, prosecution of the claims of Groups I-III would not place a substantially greater burden on the Examiner. Applicants therefore respectfully request that the Examiner withdraw the Restriction Requirement and consider all the claims together.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300

60041316 v1